Cilengitide CAS:188968-51-6

Cilengitide is primarily used to treat solid tumors, especially malignant gliomas. As an integrin inhibitor, it inhibits the angiogenesis and diffusion process of tumors by blocking the binding of tumor cells to surrounding blood vessels. Glioblastoma treatment: Cilengitide is widely studied and applied to malignant gliomas (such as glioblastoma and glioma), which are highly sensitive to its effect of inhibiting integrin receptors. By reducing tumor angiogenesis, Cilengitide can improve patients' survival and quality of life. Tumor metastasis prevention: In addition to directly inhibiting tumor growth, Cilengitide has shown potential to prevent the spread and metastasis of tumor cells in the body. This is essential to prevent tumor recurrence and metastasis to other sites. Clinical trials and studies: In recent years, Cilengitide has shown some efficacy and safety in clinical trials as a single agent or in combination with other treatments, such as radiation and chemotherapy. Research is also exploring its potential for use in the treatment of other tumor types, particularly those that rely on integrin-mediated tumor types. Overall, Cilengitide, as an integrin inhibitor, offers a new therapeutic strategy by interfering with the interaction of tumor cells with their surroundings, which holds promise for patients with malignant tumors and may expand its application in multiple tumor therapies in future studies.